- In January 2025, Zoetis announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio and Simparica Chewables, expanding their use to include the treatment and control of infestations caused by Haemaphysalis longicornis (Asian longhorned tick) in dogs aged eight weeks and older, weighing 2.8 pounds or more. With this new claim, Simparica Trio now offers the most comprehensive tick protection in its class and remains the leading combination parasiticide for dogs, having treated over 13 million dogs since its launch in 2020.
- In November 2024, Merck Animal Health announced that the European Commission has granted marketing authorization for BRAVECTO TriUNO, an innovative formulation of BRAVECTO (fluralaner) for dogs that addresses both internal and external parasites. This three-in-one chewable tablet will be available exclusively through licensed veterinarians. The product has also received approval from regulatory authorities in Peru, Guatemala, Nicaragua, and Costa Rica.
- In October 2024, Elanco Animal Health Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), making it the most comprehensive canine oral parasiticide, providing protection against six types of parasites: fleas, ticks, heartworms, and three major intestinal parasites—roundworms, hookworms, and tapeworms. Credelio Quattro is a single, monthly chewable tablet designed for dogs aged eight weeks and older.
- In April 2024, Boehringer Ingelheim announced the launch of NexGard SPECTRA (afoxolaner and milbemycin oxime) in India, following approval from the Central Drugs Standard Control Organisation (CDSCO). Building on the successful introductions of its NexGard product range—NexGard® X and L in 2020, and NexGard S and M (afoxolaner) in 2023—this launch marks an expansion of the NexGard line, now available for dogs aged two months and weighing 2 kg or more.
- In May 2023, Merck Animal Health announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved a new injectable formulation of BRAVECTO (fluralaner). This product is designed for the treatment and prevention of flea (Ctenocephalides felis) infestations for 12 months, control of paralysis tick (Ixodes holocyclus) for 12 months, control of brown dog tick (Rhipicephalus sanguineus) for 11 months, and management of flea allergy dermatitis (FAD).
